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The transcription factor IRF3 is a central regulator of
type I interferon (IFN) signaling. The mechanisms
underlying deactivation of IRF3 are poorly under-
stood although many studies suggest that IRF3
activity is terminated through degradation after viral
infection. Here we report that IRF3 is deactivated
via dephosphorylation mediated by the serine and
threonine phosphatase PP2A and its adaptor protein
RACK1. The PP2A-RACK1 complex negatively regu-
lated the IRF3 pathway after LPS or poly(I:C) stimula-
tion or Sendai virus (SeV) infection. After challenge
with LPS, poly(I:C), or low-titer SeV, activated IRF3
was dephosphorylated and returned to resting
state without being degraded, although high-titer
SeV infection triggered the degradation of IRF3.
Furthermore, PP2A-deficient macrophages showed
enhanced type I IFN signaling upon LPS, poly(I:C),
and SeV challenge and protected mice from lethal
vesicular stomatitis virus infection. Therefore,
dephosphorylation of IRF3 is a deactivation mecha-
nism that contributes to termination of IRF3-type I
IFN signaling.
INTRODUCTION
Innate immunity is the first line of host defense against pathogen
invasion. After recognition of pathogen-associated molecular
patterns (PAMPs), pathogen recognition receptors (PRRs)
activate innate immune signaling pathways, via activation of
NF-kB, inflammasomes, and type I interferons (IFNs) (Takeuchi
and Akira, 2010). Interferon regulatory factor 3 (IRF3), a central
regulator of type I interferon (IFN) signaling, is constitutively
expressed and localizes to the cytoplasm of resting cells. Once
activated by certain PRRs, such as retinoic acid-inducible
gene 1 (RIG-I), melanoma differentiation-associated protein 5
(MDA5), and Toll-like receptor 3 (TLR3) and TLR4 (Alexopoulou
et al., 2001; Andrejeva et al., 2004; Hajjar et al., 2002; Yoneyamaet al., 2004), IRF3 is phosphorylated at several serine and
threonine residues within its C-terminal trans-activation domain
by the upstream kinases tank binding kinase 1 (TBK1) and Inhib-
itor-kB kinase ε (IKKε) (Fitzgerald et al., 2003; Sharma et al.,
2003). This process leads to dimerization of IRF3 and its sub-
sequent translocation from the cytoplasm to the nucleus, where
IRF3 activates the expression of type I IFNs and interferon-stim-
ulated genes (ISGs).
Despite extensive studies on the mechanisms that activate
IRF3, the molecular machinery that is involved in IRF3 deactiva-
tion remains elusive. Once activated, the activity of IRF3 must be
switched off in time because overactive IRF3 signaling will result
in unwanted issues, such as inflammatory skin disease, septic
shock syndrome, or autoimmune disorders (Decker et al.,
2005; Kovalenko et al., 2009; Salloum and Niewold, 2011; Theo-
filopoulos et al., 2005).
Previous studies indicate that host cells utilize two mecha-
nisms to decrease the transcriptional activity of activated IRF3.
The first and foremost mechanism is proteasome-mediated
degradation of IRF3 triggered by virus-dependent phosphoryla-
tion of IRF3 (Lin et al., 1998). Peptidylprolyl cis-trans isomerase,
NIMA-interacting 1 (Pin1), Cullin-based ubiquitin ligases, and
RBCC protein interacting with PKC1 (RBCK1) are involved in
this process (Bibeau-Poirier et al., 2006; Saitoh et al., 2006;
Zhang et al., 2008), and RTA-associated ubiquitin ligase
(RAUL) is the major endogenous ubiquitin E3 ligase for IRF3
and IRF7 (Yu and Hayward, 2010). The second mechanism is
SUMOylation at K152 of IRF3, which is not dependent on its
phosphorylation, and vice versa (Kubota et al., 2008).
However, several questions remain. TBK1 and IKKε phosphor-
ylate the C-terminal domain of IRF3 to control its activation and
nuclear translocation, but it is still not known whether IRF3 can
be dephosphorylated in vivo by a phosphatase. In addition to
RNA-virus infection, which is detected by the RIG-I-like recep-
tors (RLRs), LPS and poly(I:C) stimulation also triggers the phos-
phorylation and activation of IRF3. However, it is unclear exactly
how the transcriptional activity of IRF3 is switched off after TLR4
and TLR3 stimulation.
Here we report that the serine and threonine protein phos-
phatase 2A (PP2A) is an in vivo phosphatase for IRF3 and that
after TLR3 or TLR4 stimulation, IRF3 is dephosphorylated and
returns to the resting state instead of being degraded.Immunity 40, 515–529, April 17, 2014 ª2014 Elsevier Inc. 515
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RACK1-PP2A Complex Deactivates IRF3Moreover, dephosphorylation of IRF3 also plays an important
role in RNA-virus (SeV) infection. The interaction between IRF3
and PP2A is mediated by the adaptor protein RACK1. The
RACK1-PP2A complex is found to transiently dissociate from
IRF3 upon LPS, poly(I:C), and SeV challenge. In vivo, PP2A defi-
ciency promotes the expression of Ifnb1 in macrophages and
protects mice from lethal VSV infection. Taken together, our
studies reveal that RACK1-PP2A-mediated dephosphorylation
is essential for the termination of active IRF3, which may help
in the development of novel therapeutic strategies for type I
IFN deregulation; Our results indicate that the host defense
system utilizes the dephosphorylation mechanism to deactivate
IRF3 after TLR3 and TLR4 challenge and moderate RIG-I
stimulation.
RESULTS
RACK1 Negatively Regulates the Type I IFN pathway
To identify negative regulators of type I IFN signaling, we per-
formed high-throughput screening of a human cDNA library of
a 293-TLR3 cell line stably expressing a luciferase reporter that
was driven by the IFN-b promoter (293-TLR3-IFNb cell), and
we identified RACK1 as a suppressor of the IFN-b promoter.
As shown in Figure 1A, RACK1 repressed IFN-b promoter activ-
ity in a dose-dependent manner in 293T cells in the resting state.
Additionally, ectopic expression of RACK1 suppressed poly(I:C)-
and SeV-induced IFN-b promoter activity in 293 cells in a dose-
dependent manner. ISRE is an enhancer motif that is recognized
by activated IRF3 or IRF7 and is required for the transcription of
IFN-induced genes. Therefore, we utilized an ISRE luciferase
reporter to further investigate the repressive effect of RACK1
on type I IFN signaling. As shown in Figure 1B, RACK1 sup-
pressed the activity of the ISRE promoter both in the resting state
and upon poly(I:C) and SeV stimulation. Next, we investigated
whether RACK1 influenced the expression of IFNB1 and ISGs.
Consistent with the observations above, ectopic expression of
RACK1 downregulated the gene expression of IFNB1, ISG15,
and RANTES that was induced by poly(I:C) and SeV (Figure 1C).
These results suggest that RACK1 is a negative regulator of type
I IFN signaling.
We then asked whether the specific knockdown of endoge-
nous RACK1 could enhance type I IFN signaling. Lentiviral-
based RNAi was employed to knock down endogenous
RACK1 in 293 cells (Figure 1D). RACK1 knockdown activated
IFN-b and ISRE promoter both in the resting state and after stim-Figure 1. RACK1 Inhibits the Type I IFN Pathway
(A and B) 293 cells were transfected with IFN-b (A) or ISRE (B) promoters, toget
activity wasmeasured 24 hr later. 293-TLR3 stable cells or 293T cells were transfe
promoter, together with Renilla-TK. 24 hr later, the cells were treated with poly(I:
(C) 293-TLR3 cells or 293T cells that were transfected with empty vector or RACK
RNA was harvested and the expression of IFNB1, RANTES, and ISG15 were det
(D) 293 cells were transiently transfected with shRNA targeting RACK1. Cells we
(E and F) Knockdown of RACK1 potentiated the IFN-b (E) and ISRE (F) promoter
(G) Knockdown of RACK1 potentiated gene expression of IFNB1, RANTES, and
(H) 293T cells, pretreated with poly(I:C) or not, were infected with VSV for 24 hr.
(I and J) RAW cells were infected with adenoviral-expressing scramble (con) o
expression of Rack1 (I), Ifnb1, Rantes, and Isg15 (J) by qRT-PCR. The results we
All experiments were performed three times with similar results. For reporter assa
mean ± SD, n = 2.ulation with poly(I:C) or SeV (Figures 1E and 1F). Furthermore,
the knockdown of endogenous RACK1 dramatically increased
IFNB1, ISG15, andRANTESmRNA that was induced by poly(I:C)
and SeV in 293 cells (Figure 1G).
The suppression of type I IFN signaling by RACK1 promoted
us to further explore the role of RACK1 in the cellular antiviral
response. In a standard plaque assay, knockdown of RACK1
suppressed vesicular stomatitis virus (VSV) replication in 293
cells. Moreover, pretreating the cells with poly(I:C) further
enhanced the inhibition of VSV replication induced by knock-
down of RACK1 (Figure 1H).
To exclude the possibility that negative regulation of type I IFN
signaling by RACK1 was cell type specific, we further knocked
down RACK1 expression in the murine macrophage cell line
RAW264.7 by an adenoviral-RNAi-system (Figure 1I). As
shown in Figure 1J, Rack1 knockdown increased Ifnb1, Isg15,
and Rantes mRNA induced by LPS, poly(I:C), and SeV, which
further confirmed the general function of RACK1 in the regulation
of type I IFN signaling and cellular antiviral response.
Because TLR3, TLR4, and RIG-I signaling converge at TNF
receptor-associated factor 3 (TRAF3) and because RACK1 could
repress TLR4- (LPS), TLR3- (poly(I:C)), and RIG-I- (SeV) induced
type I IFN signaling, we concluded that RACK1 functioned at or
downstream of TRAF3.
RACK1 Inhibits Type I IFN Signaling through Interaction
with IRF3
To determine how RACK1 functions in type I IFN signaling, we
performed a series of reporter assays by cotransfecting
plasmids expressing RACK1 and an IFN-b reporter with RIG-I,
MAVS, TBK1, IRF3, or IRF3-5D (a constitutively active form of
IRF3). Ectopic expression of RACK1 inhibited activation of the
IFN-b reporter that was induced by RIG-I, MAVS, TBK1, and
IRF3 but did not affect activation by IRF3-5D (Figure 2A). These
results suggest that RACK1 negatively regulates IFN-b signaling
by acting on IRF3.
Considering that RACK1 is a scaffold protein, we then deter-
mined whether RACK1 could interact with IRF3. As shown in Fig-
ure 2B, ectopically expressed IRF3 immunoprecipitated with
RACK1 in 293T cells. This interaction was again confirmed by
a GST pulldown assay (Figure 2C), which showed that a GST-
RACK1 fusion protein effectively pulled down endogenous
IRF3 from 293T cell lysates. To investigate whether the inter-
action between RACK1 and IRF3 was direct, we performed a
GST pulldown assay after incubation of the purified GST-IRF3her with Renilla-TK and increasing amounts of RACK1 plasmid. The promoter
cted with empty vector or RACK1-expressing plasmid with IFN-b (A) or ISRE (B)
C) (20 mg/ml, 6 hr) or SeV (50 HAU/ml, 10 hr).
1 expression plasmid were treated with poly(I:C) for 6 hr or SeV for 10 hr. Then,
ected by qRT-PCR. The results were normalized to ATCB mRNA.
re harvested for immunoblotting 96 hr later.
s at basal level as well as upon poly(I:C) and SeV challenges in 293 cells.
ISG15 that were induced by poly(I:C) and SeV in 293 cells.
VSV titers were determined through standard plaque assays.
r RACK1 knockdown sequences for 5 days. Then, RNA was isolated for the
re normalized to Rn18s RNA.
ys, the bar graphs show mean ± SD, n = 3. For qRT-PCR, the bar graphs show
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Figure 2. RACK1 Associates with and Inhibits IRF3 to Suppress the Type I IFN Signaling
(A) 293T cells were transfected with the IFN-b reporter construct and TK-renilla with vector expressing RIG-I, MAVS, TBK1, IRF3, or IRF3-5D and empty vector or
RACK1-expressing plasmid for 24 hr and examined by a dual luciferase assay.
(B–E) IRF3 interacted with RACK1 in exogenous IP (IP with anti-HA and anti-myc in B), GST pull down (IP with GST-RACK1 in C or GST-IRF3 in D), and
endogenous IP (IP with anti-total-IRF3, tIRF3 in E) assays.
(F) HA-IRF3 was cotransfected with myc-RACK1-truncated mutants into 293T cells. 24 hr later, IP assays were performed with anti-HA.
(G) Myc-RACK1 was transfected with HA-IRF3-truncated mutants into 293T cells. 24 hr later, IP assays were performed with anti-HA.
All experiments were performed three times with similar results. See also Figure S1.
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that His-RACK1 interacted with GST-IRF3 but not with GST,
which demonstrated that the interaction between RACK1 and
IRF3 was direct (Figure 2D). The endogenous immunoprecipita-
tion assay by an IRF3 antibody further confirmed the interaction
between IRF3 and RACK1 (Figure 2E). We found that RACK1
transiently dissociated from IRF3 upon challenge with LPS,
poly(I:C), and SeV (Figure S1A available online).
To further elucidate the interaction between IRF3 and RACK1,
we mapped the domains that were responsible for the interac-518 Immunity 40, 515–529, April 17, 2014 ª2014 Elsevier Inc.tion of both proteins. Because RACK1 is an adaptor protein
containing seven WD40 repeats, we first investigated the inter-
action between IRF3 and two RACK1 mutants: WD1-4 (WD5-7
was depleted) and WD5-7 (WD1-4 was depleted). As shown in
Figure S1B, IRF3 interacted with WD1-4 but not with WD5-7,
suggesting that the docking site of IRF3 was contained within
WD1-4. Next, we depleted WD1 (WD2-7) and WD1-2 (WD3-7)
from RACK1 and found that depletion of WD1 (WD2-7) did not
influence the interaction between IRF3 and RACK1, whereas
depletion of WD1-2 (WD3-7) abolished the interaction between
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RACK1-PP2A Complex Deactivates IRF3them (Figure 2F), indicating that WD2 of RACK1 was responsible
for the RACK1-IRF3 interaction.
IRF3 is composed of an N-terminal DNA binding domain
(DBD), an IRF association domain (IAD), a C-terminal regulatory
domain (RD), and a nuclear export sequence (NES). In the resting
state, the N- and C-terminal autoinhibitory structures interact
with each other as well as with the IAD to form a compact struc-
ture (Qin et al., 2003). Depletion of the RD containing the
C-terminal autoinhibitory structure did not affect the IRF3-
RACK1 interaction. However, depletion of RDwith IAD abolished
the interaction between IRF3 and RACK1, which suggested that
IRF3 interacted with RACK1 via its IAD. In addition, depletion of
the DBD (containing the N-terminal autoinhibitory structure) of
IRF3 led to an enhanced IRF3-RACK1 interaction, and depletion
of DBD together with NES further potentiated the IRF3-RACK1
interaction. These observations indicate that the docking site
of RACK1 on the IAD is hidden from the DBD and NES domains
of IRF3. Taken together, our results suggest that the WD2 of
RACK1 and IAD of IRF3 are responsible for their interaction
(Figure 2G).
We also investigated the interactions of RACK1 with other
components of the type I IFN pathway. As shown in Figures
S1C–S1F, RACK1 did not interact with TLR3, TIR-domain-
containing adaptor-inducing interferon-b (TRIF), TRAF3, or
TBK1 in the resting state or upon poly(I:C) challenge. These
results were consistent with our previous finding that RACK1
inhibited type I IFN signaling through interaction with IRF3.
RACK1 Suppresses the Phosphorylation and Activation
of IRF3
The interaction between RACK1 and IRF3 caused us to examine
whether this interaction influenced the activation of IRF3. First,
we found that knockdown of RACK1 potentiated transfected
poly(I:C) (RIG-I) and triggered IRF3 S396 phosphorylation and
dimerization in HeLa cells (Figure 3A). S396 is the minimal phos-
phoacceptor site that is required for in vivo activation of IRF3 in
response to virus and dsRNA (Servant et al., 2003). A similar
result was observed in RACK1 knockdown 293T cells. We also
found that enhanced phosphorylation and dimerization of IRF3
caused by knockdown of RACK1 could be rescued by reintro-
ducing an siRACK1-resistant myc-RACK1 mutant (Figure 3B).
Because phosphorylation-triggered IRF3 dimerization initiates
the nuclear translocation of IRF3, we further investigated
whether overexpression or knockdown of RACK1 affected this
process. We found that overexpression of RACK1 suppressed
the phosphorylation and nuclear translocation of IRF3 that
was triggered by poly(I:C) transfection, whereas knockdown
of RACK1 had the opposite effect (Figures S2A and S2B). As
shown in Figure 1, RACK1 inhibited TLR3- and RIG-I-induced
type I IFN signaling, and therefore we determined whether
RACK1 could restrain poly(I:C)- and SeV-induced IRF3 phos-
phorylation. As expected, ectopic expression of RACK1
reduced the IRF3 phosphorylation and duration induced by
poly(I:C) and SeV in 293 cells (Figure 3C), whereas knockdown
of RACK1 enhanced the IRF3 phosphorylation and duration
induced by poly(I:C) and SeV (Figure 3D). The effects of
RACK1 on IRF3 phosphorylation were also observed in the
murine macrophage cell line RAW264.7, which indicated that
the effect of RACK1 on IRF3 phosphorylation is conservedacross species (Figure 3E). With the adenoviral-RNAi-system,
we transiently knocked down RACK1 expression in RAW264.7
cells, which led to the potentiated duration and phosphorylation
of IRF3.
RACK1-Interacting-Phosphatase PP2A Inhibits Type I
IFN Signaling
RACK1 recruits the phosphatase PP2A to modulate the activity
of Inositol-Requiring Enzyme-1a (IRE1a) (Qiu et al., 2010).
Additionally, considering the fact that RACK1 did not suppress
IFN-b promoter activity induced by phospho-mimic IRF3-5D
and the fact that RACK1 negatively regulated IRF3 phosphory-
lation, we hypothesized that RACK1 represses type I IFN
signaling by promoting the dephosphorylation of IRF3 via
recruiting the phosphatase PP2A. We first tested this hypo-
thesis through immunoprecipitation experiments. Ectopically
expressed HA-IRF3 interacted with endogenous PP2A-Ca,
which is the most abundant catalytic subunit of the phospha-
tase PP2A (Figure 4A). Furthermore, total-IRF3 immunoprecip-
itated with PP2A-Ca in an endogenous IP assay (Figure 4A).
These data indicate that PP2A regulates type I IFN signaling.
Although the ectopic expression of PP2A-Ca only partially sup-
pressed RIG-I-induced IFN-b promoter activity in 293T cells,
treatment with the PP2A agonist C2-ceramide potently
repressed poly(I:C)-induced IFN-b promoter activity in 293-
TLR3-IFNb cells (Figure 4B). Consistently, the PP2A inhibitor
(OA) potentiated poly(I:C)- and SeV-induced IFN-b promoter
activity (Figure 4C). Meanwhile, the activation of PP2A by C2-
ceramide suppressed IRF3-S396 phosphorylation induced by
poly(I:C) and LPS (Figure 4D). Moreover, two PP2A inhibitors,
OA and CA, led to upregulated IRF3-S396 phosphorylation in
293-TLR3 cells (Figure 4E). Similar observations were found in
primary human peripheral blood mononuclear cells (PBMCs)
that were treated with OA and C2-ceramide (Figures S3A and
S3B). Because OA treatment induced the phosphorylation of
IRF3, we then examined whether this treatment induced ISG’s
expression and found that OA treatment indeed enhanced
the promoter activity of IFN-b and RANTES in 293T cells
(Figure S3C).
Then, we specifically knocked down the expression of Ppp2ca
in RAW264.7 cells. It was found that IRF3 phosphorylation and
duration were enhanced in PP2A-Ca knockdown cells after
LPS, poly(I:C), and SeV challenge (Figure 4F). Consistent with
these findings, commercialized PP2A protein dephosphorylated
IRF3 in vitro, and the dephosphorylation effect of PP2A on IRF3
was enhanced by the PP2A agonist C2-ceramide and was
inhibited by the PP2A inhibitor OA (Figure 4G). Taken together,
these results imply that PP2A negatively regulates type I IFN
signaling by dephosphorylating IRF3.
Because multiple amino acids of IRF3 could be phosphory-
lated upon activation, we then investigated whether PP2A
targeted other amino acids in addition to S396. First, we
found that overexpression of PP2A or activation of PP2A by
using the agonist C2-ceramide suppressed IRF3-S396D-
induced IFN-b promoter activity (Figures S3D and S3E). These
results indicate that PP2A may target other amino acids in
addition to S396 of IRF3. Further experiments showed that
inhibition of PP2A by treating with OA induced the phosphory-
lation of IRF3 at multiple amino acids including S386, S396,Immunity 40, 515–529, April 17, 2014 ª2014 Elsevier Inc. 519
Figure 3. RACK1 Suppresses the Phosphorylation and Activation of IRF3
(A) 72 hr after RNAi treatment, the HeLa cells were transfected with poly(I:C) for the indicated times.
(B) 72 hr after RNAi treatment, the 293T cells were transfected with empty vector or the shRNA-resistant RACK1 construct for 24 hr before poly(I:C) transfection.
(C) 293-TLR3 or 293T cells that were transfected with empty vector or the RACK1 constructs were challenged with poly(I:C) (20 mg/ml) or SeV (400 HAU/ml) for the
indicated times.
(D) 96 hr after RNAi, the 293-TLR3 or 293T cells were challenged with poly(I:C) or SeV, as in Figure 1.
(E) 5 days after RNAi treatment, the RAW264.7 cells were challenged with LPS (100 ng/ml), poly(I:C) (50 mg/ml), and SeV (40 HAU/ml).
All experiments were performed three times with similar results. See also Figure S2.
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RACK1-PP2A Complex Deactivates IRF3and S398 (Figure S3F). We also found that knockdown of
PP2A-Ca potentiated the phosphorylation of IRF3 at S386,
S396, and S398 upon poly(I:C) transfection (Figure S3G). These520 Immunity 40, 515–529, April 17, 2014 ª2014 Elsevier Inc.results suggest that PP2A negatively regulates IFN-b induction
by dephosphorylating IRF3 at multiple amino acids of its C
terminus.
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PP2A Complex and Promotes the Dephosphorylation of
IRF3
To investigate whether RACK1 and PP2A form a complex that
regulates the activity of IRF3, we performed endogenous IP
assays with IRF3 and PP2A-Ca antibodies. Antibodies against
endogenous IRF3 simultaneously precipitated RACK1 and
PP2A-Ca, and anti-PP2A-Ca precipitated IRF3 as well as
RACK1 (Figure 5A). These observations, together with the data
shown in Figures 1A, 1B, and 4A, suggest that RACK1 may
form a complex with PP2A in the resting state that maintains
low IRF3 phosphorylation. Therefore, we tested whether the
adaptor protein RACK1 mediated the interaction between IRF3
and the phosphatase PP2A. Consistent with this hypothesis,
we found that ectopic expression of RACK1 enhanced the inter-
action between IRF3 and PP2A-Ca (Figure 5B), whereas knock-
down of RACK1 impaired the interaction between them (Figures
5C and 5D). Moreover, after knockdown of RACK1, the PP2A-
agonist C2-ceramide almost lost its ability to promote IRF3
dephosphorylation upon LPS stimulation (Figure 5E). On the
other hand, CA-induced inhibition of PP2A was enhanced
when RACK1 was knocked down, which led to an accelerated
accumulation of IRF3 phosphorylation (Figure 5F). These obser-
vations suggest that PP2A modulates the phosphorylation of
IRF3 in a RACK1-dependent manner. Furthermore, endogenous
IP showed that RACK1 constantly interacted with PP2A, and
IRF3 transiently dissociated from the RACK1-PP2A complex
upon poly(I:C) challenge (Figures 5G and 5H). These results sug-
gest that RACK1 mediates the formation of the IRF3-RACK1-
PP2A complex and promotes the dephosphorylation of IRF3.
Because RACK1 mediated formation of the IRF3-RACK1-
PP2A complex and negatively regulated IRF3 phosphorylation,
we then investigated the subcellular localization of IRF3 and
RACK1. IRF3 and RACK1 colocalized in the cytoplasm at the
resting state. Upon poly(I:C) stimulation, RACK1 stayed in the
cytoplasm, while most of the IRF3 molecules dissociated from
RACK1 and translocated into the nucleus. Moreover, at the later
stage of poly(I:C) stimulation, IRF3 reinteracted with RACK1 in
the cytoplasm (Figure S2C). These results were consistent
with the data in Figures 5G and 5H, which showed that IRF3
transiently dissociated from the RACK1-PP2A complex upon
poly(I:C) challenge and that IRF3 reinteracted with the RACK1-
PP2A complex at the later stage of stimulation.
PP2A Depletion Enhances the Expression of Ifnb1 and
Protects Mice from Lethal VSV Infection
To further investigate the biological function of IRF3 dephos-
phorylation, we generated macrophage-specific PP2A-deficient
mice by crossing Ppp2ca floxed mice with LysM-Cre mice (Fig-
ure 6A). We first checked the phosphorylation of IRF3 and Ifnb1
expression upon stimulation by LPS, poly(I:C), and SeV in perito-
neal macrophages from wild-type (WT) and PP2A-deficient
mice. As shown in Figures 6B–6E, depletion of PP2A-Ca poten-
tiated IRF3 phosphorylation and the expression of Ifnb1 induced
by LPS, poly(I:C), and SeV. To confirm that the changes
observed in the knockout cells were directly attributable to
PP2A-Ca, we reconstituted the expression of PP2A-Ca and
examined the activation of IRF3 and expression of Ifnb1 after
stimulations. As shown in Figures S4A and S4B, re-expressionof PP2A-Ca in PP2A-deficient cells suppressed the phosphory-
lation of IRF3 and the expression of Ifnb1 similar to that observed
in WT cells. We also found that the PP2A inhibitor (OA) and
activator (C2-ceramide) lost their effects in PP2A-deficient cells
(Figure S4C). These data support the data suggesting that PP2A
is a phosphatase that targets IRF3.
Considering the fact that depletion of PP2A-Ca increased the
expression of Ifnb1, the host antiviral response could be elevated
in PP2A-deficient cells. Therefore, we tested the virus replication
ability in PP2A-deficient and WT primary macrophages. Consis-
tent with the above results, we found that VSV replication was
significantly suppressed in primary PP2A-deficient peritoneal
macrophages (Figure 6F).
To further elucidate the role of PP2A in type I IFN signaling, we
performed a series of experiments under physiological condi-
tions. First, we injected WT and PP2A-deficient mice with VSV
through the tail vein. We found that the depletion of PP2A-Ca
significantly protectedmice from lethal VSV infection (Figure 6G).
Next, we challenged the PP2A-deficient and control mice with
VSV by intravenous injection at different time points, collected
PBMCs, and immediately analyzed the IRF3 phosphorylation
level and gene expression of Ifnb1, Isg15, and Rantes in the
monocytes. We found that 12 hr after VSV infection, IRF3
remained phosphorylated in PP2A-deficient PBMCs, whereas
the IRF3 phosphorylation level in WT PBMCs was decreased
(Figure 6H). Meanwhile, PP2A-deficient PBMCs produced
more Ifnb1, Isg15, and Rantes than did WT PBMCs (Figure 6I).
We also found that the VSV titer in the serum of PP2A-deficient
mice was much lower than that of control mice, which demon-
strated that depletion of PP2A-Ca indeed suppressed VSV repli-
cation in vivo (Figure 6J). Thus, PP2A is an in vivo phosphatase
that targets IRF3, and depletion of PP2A-Ca potentiates the
phosphorylation of IRF3 and the transcription of the Ifnb1.
Furthermore, inactivation of PP2A helped the host to suppress
virus replication.
Because PP2A modulates TLR4 signaling, we then investi-
gated whether depletion of PP2A-Ca affects LPS-induced endo-
toxin shock.We found that PP2A-deficient mice diedmuchmore
rapidly than did WT mice upon LPS challenge (Figure S4D). We
also detected enhanced IRF3 phosphorylation and Ifnb1 expres-
sion in PBMCs from PP2A-deficient mice after intraperitoneal
injection of LPS (Figures S4E and S4F). These data indicate
that PP2A dephosphorylates IRF3 in vivo. These data are also
consistent with previous reports showing that IRF3 and IFN-b
are essential for LPS-induced lethality (Karaghiosoff et al.,
2003; Sakaguchi et al., 2003). At the same time, enhanced
NF-kB signaling was also detected in PBMCs from PP2A-defi-
cient mice. We found that PP2A-deficient PBMCs produced
more Tnf than did WT PBMCs (Figure S4G), consistent with
previous data showing that PP2A is a negative regulator of
NF-kB signaling (Li et al., 2006; Witt et al., 2009; Yang et al.,
2001). Thus, depletion of PP2A-Ca induces enhanced NF-kB
and IRF3-type I IFN signaling, both of which probably contribute
to LPS-induced endotoxin shock.
IRF3 Is Dephosphorylated after LPS, Poly(I:C), and SeV
Challenges
The RACK1-PP2A complex controls the activity of IRF3 after
TLR3, TLR4, and RIG-I stimulation. LPS (TLR4) stimulationImmunity 40, 515–529, April 17, 2014 ª2014 Elsevier Inc. 521
(legend on next page)
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IRF3 degradation (Figure S5A, Figures 3E and 4F) and did not
affect IRF3 protein stability after the blockade of protein synthe-
sis by cycloheximide (CHX) treatment (Figure S5B), indicating
that the IRF3 activity induced by TLR4 was not switched off in
a proteosome-dependent manner. It is widely accepted that
K48-linked, polyubiquitination-mediated IRF3 degradation is
the primarymechanism for switching off the activity of phosphor-
ylated IRF3 activated by viral infection. Although poly(I:C) (TLR3)
treatment was reported to induce the degradation of ectopically
expressed IRF3 through a Pin1-accelerated process (Saitoh
et al., 2006), TLR3 stimulation did not affect the stability of the
endogenous IRF3 protein and the explanation for the differing
response of endogenous and exogenous IRF3 in response to
TLR3 stimulation is not clear. Consistently, we found that treating
293-TLR3, RAW264.7, and HeLa cells with poly(I:C) did not
trigger the degradation of endogenous IRF3 (Figures S5C–
S5E). Moreover, no report has determined whether IRF3 activity
is switched off through the degradation of the IRF3 protein
upon TLR4 stimulation. Therefore, we then determined whether
saturated-strength poly(I:C) and LPS challenge triggered the
degradation of endogenous IRF3. We found that treating 293-
TLR3-IFNb stable cells or RAW264.7 cells with saturated-
strength doses of poly(I:C) or LPS led to IRF3 phosphorylation
and maximum activation of an IFNB1 promoter reporter
construct; however, no IRF3 degradation was observed,
although the phosphorylation of IRF3 increased and then
decreased to a basal amount (Figures 7A and 7B). These obser-
vations suggest that TLR3 and TLR4 signaling utilizes a dephos-
phorylation mechanism to terminate the activity of activated
IRF3 rather than IRF3 degradation.
It is well known that virus infection triggers IRF3 degradation.
Consistent with previous reports, we found that more than 90%
of the IRF3 protein was degraded 24 hr after SeV infection in
293T cells when exposed to a high dosage of 400 HA/ml.
However, we found that lower-titer infections of SeV, such as
40 HA/ml, caused only retarded mobility of most of the IRF3
protein in an SDS-gel, which indicated hyperphosphorylation
of IRF3, without triggering the degradation of IRF3 at 24 hr
postinfection (p.i.). Meanwhile, the phosphorylation of IRF3-
S396 reached its maximum at 12 hr p.i. and decreased at 24 hr
p.i. (Figure 7C). A similar result was observed in RAW264.7 cells
upon SeV infection (Figure 7D). Next, we monitored 40 HA/ml
SeV infection within a 72 hr time window in 293T cells. Surpris-
ingly, we found that the IRF3 protein remained in a retarded
migrating form (migrated slower in the gel, indicating IRF3-402,
-404, -405 phosphorylation) (Cle´ment et al., 2008), whereas
phosphorylation of IRF3-S396 and the IFNB1 mRNA decreasedFigure 4. PP2A Negatively Regulates the Type I IFN Pathway
(A) 24 hr after transfection of HA-IRF3 into 293T cells, IP assays were performed
(B) Overexpression of PP2A-Ca partially inhibited IFN-b promoter activity, where
promoter activity.
(C) A PP2A inhibitor, OA, potentiated poly(I:C)- and SeV-induced IFN-b promote
(D) The PP2A agonist C2-ceramide repressed poly(I:C)- and LPS-induced IRF3 p
(E) PP2A inhibitors OA and CA induced the accumulation of IRF3 phosphorylatio
(F) Knockdown of PP2A-Ca potentiated the phosphorylation and duration of IRF
(G) Flag-IRF3 was immunoprecipitated from 293T cells that were infected with S
PP2A inhibitor CA or the PP2A agonist C2-ceramide in vitro.
All experiments were performed three times with similar results. See also Figureat 72 hr p.i. (Figure 7E). Similar observations were found in A549
cells upon low-titer SeV infection (Figure S5F). These data indi-
cate that phosphorylation of IRF3-S396 correlates with the tran-
scriptional activity of IRF3, which is consistent with a previous
report that S396 phosphorylation is critical for IRF3 dimerization
and interaction with CBP (Cle´ment et al., 2008).
Because IRF3 was more efficiently dephosphorylated by
PP2A during TLR stimulation when compared to low-titer
SeV infection, we then investigated the mechanistic basis for
this difference. We found that PP2A activation was lower after
low-titer SeV infection compared to TLR3 and TLR4 stimulation
(Figure S5G). We also found that high-titer SeV infection utilized
both dephosphorylation and degradation to switch off the
activity of IRF3. High-titer SeV infection activated PP2A activity
early during the response but triggered a faster and increased
phosphorylation of IRF3 when compared to low-titer SeV
infection, which could exceed the dephosphorylation capability
of PP2A. Only upon high-titer SeV infection did cells utilize the
degradation mechanism to turn off the activity of IRF3 to avoid
overproduction of type I IFNs (Figure S5G). Our data indicate
that IRF3 proteins undergo dephosphorylation and are not
degraded only upon LPS, poly(I:C), and low-titer SeV challenge.
Consistent with previous work, our data show that high-titer
viral infection indeed triggered the degradation of IRF3. These
results show that dephosphorylation of IRF3 is a mechanism
to deactivate IRF3 after TLR3, TLR4, and RIG-I receptor
stimulation.
DISCUSSION
It is widely believed that kinases and phosphatases coopera-
tively control protein activity. Regulation of IRF3 activity is a
key step in innate immunity. IRF3 is reported to be activated
by the upstream kinases TBK1 and IKKε. However, the phospha-
tase responsible for dephosphorylation of IRF3 has been elusive.
Investigation of RACK1, a newly identified negative regulator of
IRF3-type I IFN signaling, led to identification of PP2A as a
phosphatase that regulates activity of IRF3 in vivo. Moreover,
we found that deactivation of IRF3 upon LPS, poly(I:C), and
low-titer SeV challenge is primarily dependent on IRF3 dephos-
phorylation rather than IRF3 degradation. Severe SeV infection
also activated the activity of PP2A, although the process of
IRF3 degradation was initiated at a later stage of infection. These
results indicate that the host defense system utilizes a dephos-
phorylation strategy to terminate IRF3 activity and that degrada-
tion of IRF3 as a mechanism for deactivation is restricted for
high-titer virus infection. Thus we propose that dephosphory-
lation is a major mechanism to deactivate IRF3 and thatwith anti-HA.
as a PP2A agonist, C2-ceramide, potently suppressed poly(I:C)-induced IFN-b
r activity.
hosphorylation in RAW264.7 cells.
n.
3 activation in RAW264.7 cells induced by LPS, poly(I:C), and SeV.
eV or not, then treated with different doses of PP2A protein together with the
s S3 and S6.
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Figure 5. RACK1 Mediates the Formation of IRF3-RACK1-PP2A Complex
(A) Endogenous IPs were performed with anti-tIRF3 or anti-PP2A-Ca.
(B) Overexpression of RACK1 enhanced the interaction between IRF3 and PP2A-Ca.
(C and D) Knockdown of RACK1 attenuated the IRF3-PP2A-Ca interaction. IP assays were performed with anti-HA (IRF3) antibody (C) or anti-myc (PP2A-Ca)
antibody (D).
(legend continued on next page)
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RACK1-PP2A Complex Deactivates IRF3IRF3-degradation process is initiated only when the dephos-
phorylation process becomes overburdened.
Among the seven serine and threonine residues within the
C-terminal domain of IRF3, S386 (cluster I) and S396 (cluster II)
were most critical for IRF3 activation (Mori et al., 2004; Servant
et al., 2003). We found that residues S386 and S396 shared
the same dynamic phosphorylation pattern after SeV infection,
indicating that S386 and S396 share the same dephosphoryla-
tion machinery (Figure S5F). Additionally, in the overexpression
or knockdown assays for RACK1, we found that modulation of
RACK1 indeed influenced S386 and S396 phosphorylation
after poly(I:C) stimulation (Figures S3H and S3I). Further investi-
gations showed that knockdown of PP2A-Ca also enhanced
both S386 and S396 phosphorylation after poly(I:C) challenge
(Figure S3G).
IRF3 and IRF7 are similar in structure and function and they
share the same kinase and the same E3 ubiquitin ligase (Sharma
et al., 2003; Yu and Hayward, 2010). As shown in Figure S6A,
overexpression of RACK1 prominently suppressed IRF7-
induced IFN-b luciferase activity in 293-TLR3 cells, and the IP
assay showed that IRF7 could interact with RACK1 and PP2A-
Ca (Figures S6B and S6C). Further experiments showed that
RACK1 did not interact with IRF1, IRF2, IRF5, IRF8, and IRF9
at the resting state or upon SeV infection (Figure S6D). We also
found that depletion of PP2A-Ca potentiated IRF7 phosphoryla-
tion in primary peritoneal macrophages (Figure S6E). These
results suggest that the dephosphorylation mechanism medi-
ated by the RACK1-PP2A complex is specific for IRF3 and
IRF7 but not for other members of the IRF family.
Finally, we propose a model for IRF3 life cycle. Through form-
ing a complex with RACK1-PP2A in the cytoplasm in resting
condition, IRF3 is kept in an inactive state. Upon stimulation,
the RACK1-PP2A complex stays in the cytoplasm and IRF3
becomes phosphorylated and translocates to the nucleus.
Once in the nucleus, IRF3 interacts with the DNA-dependent
protein kinase (DNA-PK), which phosphorylates the T135 of
IRF3; DNA-PK-dependent T135 phosphorylation of IRF3 in-
hibited nuclear export of IRF3 and prolonged the transcription
of IRF3 target genes (Karpova et al., 2002).The dephosphoryla-
tion of IRF3 on its T135 is required for the nuclear export of
IRF3 though the phosphatase targeting T135 of IRF3 is still un-
known. At the later stage of stimulation (LPS, poly(I:C), and
low-titer SeV challenge), IRF3 is exported from the nucleus and
interacts with the RACK1-PP2A complex, which dephosphory-
lates and inactivates IRF3 in the cytoplasm. Upon high-titer
SeV infection, IRF3 is degraded in the cytoplasm after being
exported from the nucleus. Thus, RACK1-PP2A acts as a critical
negative regulator of IRF3-type I IFN signaling. Our study shows
that PP2A is the first phosphatase known to target and deacti-
vate IRF3, which is the central regulator of the type I IFN
signaling. Understanding the deactivation process of IRF3 will
facilitate the development of new therapeutic strategies for
type I IFN dysregulation diseases.(E and F) si-RACK1 or si-Con RAW264.7 cells were treated with LPS plus DMS
indicated antibody, as described in (E). RACK1 knockdown or control RAW cells
were analyzed as described in (F).
(G and H) 293-TLR3 cells were challenged with 20 mg/ml poly(I:C) for different tim
All experiments were performed three times with similar results. See also FigureEXPERIMENTAL PROCEDURES
Mice and Reagents
Ppp2ca floxed mice were provided by X. Gao, Model Animal Research Center
of Nanjing University. LysM Cre mice were a kind gift from F. Wang, INS, SIBS,
CAS. The animal experiments were undertaken in accordance with the
National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Anti-pIRF3 (S396) was from Cell Signaling Technology. Anti-IRF3, anti-b-cate-
nin, anti-a-tublin, anti-c-myc, and anti-b-actin were from Santa Cruz Biotech-
nology. Anti-pGSK3b, anti-flag, anti-HA, anti-RACK1, and anti-PP2A-Ca
were from BD Biosciences. Anti-pIRF3 (S386) was from Epitomics. Anti-
pIRF3 (S398) was from Upstate. Anti-TLR3 and His-RACK1 were from Abcam.
LPS, poly(I:C), C2-ceramide, and thioglycolate were from Sigma. DuoSet IC
Human/Mouse/Rat Active PP2A kit was from R&D.
Cell Culture
HeLa, RAW264.7, U373, and 293T cell lines were from American Type Culture
Collection. 293-TLR3 and 293-TLR3-IFNb stable cells were kind gifts from C.
Wang, SIBCB, SIBS, CAS. Mouse peritoneal macrophages were induced by
thioglycolate (Yang et al., 2010). Mouse and human PBMCs were isolated
from whole blood by Percoll treatment. The study protocol was approved by
the Institutional Review Board of the Institute for Nutritional Sciences and all
participants provided written informed consent forms. All cells were cultured
in DMEM (GIBCO) with 10% FBS (Front).
Plasmid Constructs
The Flag-tagged TRIF, TRAF3, RIG-I, MAVS, and TBK1 plasmids were kind
gifts from J.H. Han, State Key Laboratory of Cellular Stress Biology, School
of Life Sciences, Xiamen University, Xiamen, China. Myc-PP2A-Ca was a
kind gift from Y. Liu, INS, SIBS, CAS. The open reading frame (ORF) of
RACK1 was cloned into pCMV-myc or pCMV-flag-tag2B. IRF3 ORF was
amplified from the cDNA of RAW264.7 and 293T and cloned into pCMV-HA
or Tag2B. IRF3-5D mutant and IRF3 truncates were constructed by PCR as
previously described (Lin et al., 1998; Yang et al., 2010).
Luciferase Reporter Assays
293T or 293-TLR3 cells were transfected with ISRE or IFN-b reporter together
with pRL-TK renilla and other described gene constructs by a standard
calcium phosphate transfection method. Then cells were lysed and luciferase
activity was measured by dual-luciferase reporter assay system according to
the manufacturer’s instructions (Promega).
RNA Interference
FG12 lentiviral vector was utilized to produce siRNA. Two sequences (6# and
31#) targeting RACK1mRNAwere as described previously (Deng et al., 2012).
Adenovirus-mediated Rack1 knockdown vectors (1# and 2#) were kind gifts
from the lab of Y. Liu (Qiu et al., 2010). Retroviral vectors carrying Ppp2ca
targeting sequence were used to knock down PP2A-Ca in RAW264.7 cells.
The targeted sequences were 3#, 50-CGTTCAAGAGGTTCGATGT-30; 6#,
50-GTGGTAACCAAGCTGCAAT-30.
RNA Extraction and Quantitative Real-Time PCR
RNA extraction and qRT-PCR analysis were performed as described (Li et al.,
2012). The primer sequences detecting human or murine IFNB1, ISG15, and
RANTES were previously described (Huang et al., 2005; Zhang et al., 2009).
GST Pull-Down Assay
The fusion protein of GST-RACK1 and GST protein were prepared as
described (Shi et al., 2012). 5 mg GST or GST-RACK1 protein was added to
293T cell lysate followed by overnight incubation with gentle rotation andO or the PP2A agonist C2-ceramide, and cell lysates were analyzed with the
were treated with the PP2A inhibitor CA for the indicated time, and cell lysates
es. IP with PP2A-Ca (G) or total-IRF3 (H) antibody.
S2.
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Figure 6. PP2A-Deficient Macrophages Transcribe More Ifnb1 and Protect Mice against Lethal VSV Infection
(A) Peritoneal macrophages were induced with FTG. Then, cell lysates were analyzed with anti-PP2A-Ca antibody.
(B–D) PP2A deficiency potentiated IRF3 phosphorylation in peritoneal macrophages induced by LPS (B), poly(I:C) (C), or SeV (D). n = 4.
(E) PP2A deficiency enhanced the gene expression of Ifnb1 that was induced by LPS, poly(I:C), and SeV.
(F) Depletion of PP2A-Ca suppressed VSV replication in primary macrophages.
(G) Mice were challenged with VSV (2 3 710 pfu/g) by intravenous injection and their survival was evaluated. *p = 0.0218 < 0.05 (Gehan Breslow Wilcoxon test).
(H–J) After VSV infection, PBMCs were isolated by centrifugation in Percoll. Half of the purified monocytes was used to analyze the pTBK1(S172), pIRF3(S396),
tIRF3, and GAPDH protein (H); the other half was used to detect Ifnb1, Isg15, and RantesmRNA by qRT-PCR (I). Serum was collected from the peripheral blood
(12 hr after VSV infection) to perform standard plaque assays (J) (n = 5), ***p = 0.00041 < 0.001 (two-tailed Student’s t test).
All experiments were performed two times with similar results. See also Figure S4.
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Figure 7. Dephosphorylation Contributes to IRF3 Deactivation after LPS, Poly(I:C), and SeV Challenge
(A) 293-TLR3-IFNb cells were treated with 10 mg/ml, 30 mg/ml, or 90 mg/ml poly(I:C) for the indicated time before harvested.
(B) Treating RAW264.7 cells with a saturated-strength LPS did not lead to IRF3 degradation.
(C) IRF3 degradation was triggered only by high-titer SeV infection (400 HAU/ml), not by a low-titer infection (40 HAU/ml) in 293T cells.
(D) IRF3 degradation was triggered only by high-titer SeV infection (250 HAU/ml), not by low-titer infections (50 and 10 HAU/ml) in RAW264.7 cells.
(E) Low-titer SeV infection did not trigger IRF3 degradation in 293T cells in a 72 hr time window.
All experiments were performed three times with similar results. See also Figure S5.
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RACK1-PP2A Complex Deactivates IRF3addition of glutathione-sepharose 4B beads for 3 hr. Beadswere washed three
times and eluted with 23SDS loading buffer.Immunoblot and Precipitation
Cell lysates that were incubatedwith the indicated antibodies for 12 hr andwith
protein A beads for another 3 hr. Beads were washed three times and eluted
with 23SDS loading buffer. Native PAGE was performed as described
(Iwamura et al., 2001).VSV Plaque Assay
293T cells were transfected with control or RACK1 RNAi plasmids. 4 days
later, cells were further mock transfected or transfected with poly(I:C) for
24 hr. Next, cells were infected with VSV (MOI = 0.1). 24 hr later, cell culture
media was harvest for plaque assay via 293A cell. Plaque assay was per-
formed as described (Zhong et al., 2008).In Vitro Phosphatase Assay
293T cells were transfected with Flag-IRF3 plasmid. 24 hr later, IP assays were
performed with anti-Flag antibody. Beads were washed three times. Immuno-
precipitated Flag-IRF3was incubatedwith different dose of recombinant PP2A
protein (Millipore) without or with PP2A inhibitor OA or agonist C2-ceramide at
30C for 30 min. Reaction was stopped by addition of 23SDS loading buffer.
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